Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of biomarkers associated with res...
Principais autores: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
Frontiers Media S.A.
2023-01-01
|
coleção: | Frontiers in Immunology |
Assuntos: | |
Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1097117/full |